XRCC4 rs1805377 and LIG4 rs1805388 polymorphisms may be useful susceptibility biomarkers for gliomas and aid in the development of diagnostic strategy to reduce the burden of gliomas. This evidence concerns the gene LIG4 and central nervous system cancer.